Lifestyle

Study: Magnolia Tree Chemical Inhibits Covid Reproduction

A new finding shows that a chemical found in the bark of the magnolia tree suppresses replication of the SARS-CoV-2 virus, which causes COVID-19, in different types of cells, and may be effective against future coronaviruses.

The researchers discovered that the chemical honokiol reduced the production of infectious SARS-CoV-2 virus particles in treated cells to roughly 1,000th of the prior level.

The study, which was published in the journal Microbiology Spectrum, also found that the compound reduced the replication of other extremely dangerous human coronaviruses, such as Middle East respiratory syndrome (MERS) and Severe acute respiratory syndrome (SARS).

Associate Professor at Leiden University, Netherlands, Martijn J. van Hemert said, “This suggests that it has a broad spectrum of activity and would likely also inhibit novel coronaviruses that might emerge in the future”.

He further said, “If honokiol can be developed into a drug, possibly in combination with other compounds, stockpiling it would help us to increase our preparedness for the emergence of the next coronavirus”.

J. van Hemert stated, “Broad-spectrum medications might then be used to treat early patients and prevent spread, or they could be used prophylactically among healthcare personnel, and in high-risk groups, such as among nursing home residents”.

“Honokiol also possesses anti-inflammatory properties which could be beneficial in cases where patients seek medical therapy at a somewhat late stage of the disease, by which time the body’s own inflammatory responses to the infection are causing symptoms”, J. van Hemert continued.

“At that point, inhibiting of virus replication may no longer be useful”, he explained, “but honokiol’s anti-inflammatory response may mitigate the illness”.

Honokiol blocks a later stage viral replication cycle, once that takes place after the virus has entered the cell.

The researchers believe that honokiol works by activating systems in the host cell that prevent viral multiplication. It did so with the initial SARS-CoV-2 variants, as well as the more recent Omicron variants.

J. van Hemert went on to say, “Our study merely provides the basis for further research into potential therapeutic applications”.

“It is vital to note that it is too early to speculate on the usage of honokiol in SARS-CoV-2 patients. This requires much more research and, if successful, properly conducted clinical trials are required”, the researcher concluded.

Also read: ‘Warm Ice Age’ Changed Earth’s Climate Cycles

Spriha Rai

Recent Posts

Hina Khan Hails 11 Years Of PM Modi’s Leadership; Highlights National Progress

As the nation marks 11 years under PM Modi's leadership, actress Hina Khan shares her…

5 hours ago

Subhash Ghai Hails PM Modi’s Transformative Vision For India

Subhash Ghai has praised PM Narendra Modi’s leadership for catalysing India’s growth and changing the…

5 hours ago

India & Central Asia Boost Rare Earth Cooperation At Delhi Meet

India and five Central Asian nations have agreed to deepen cooperation on rare earths and…

6 hours ago

PM Modi’s Beej Se Bazaar Tak Vision Reshapes Indian Agriculture

Prime Minister Modi has redefined Indian agriculture with the ‘Beej Se Bazaar Tak’ vision, transforming…

6 hours ago

EV Sales Cross 4% Mark In May; Signalling Steady Shift To Green Mobility

EV sales topped 4% of passenger vehicle retail in May 2025, signalling growing demand for…

7 hours ago

Self-Reliant Defence Industry Marks India’s Strategic Security Ascent

One year into Modi 3.0, reforms have reduced poverty, strengthened defence, and accelerated the digital…

7 hours ago